About Dier

Zhuhai Deer Bioengineering Co., Ltd. is a high-tech enterprise specializing in the R&D, manufacturing, sales, and service of diagnostic products for pathogenic microorganisms. It maintains an independent R&D laboratory and a wholly owned subsidiary in the United States. Since its establishment in 2003, the company has focused on the field of clinical microbiological diagnostics, aiming to develop automated solutions for clinical microbiology testing and providing etiological diagnostic products and services to more than 5,000 medical institutions worldwide.

Dier Biotech adheres to independent R&D, holding numerous national invention patents and other proprietary intellectual property rights, and has been recognized as an IP‑advantaged enterprise and a high‑tech company. Its core product portfolio covers microbial culture, morphological testing, identification, antimicrobial susceptibility testing, and immune‑inflammatory biomarker analysis. Leveraging automation and information‑technology innovations, the company has developed a clinical microbiology testing automation platform comprising time-of‑flight mass spectrometry for microorganisms, an automated blood‑culture subculture workstation, and a fully automated antimicrobial susceptibility testing system, dedicated to helping humanity better address the health challenges posed by infections.